Good Prognosis in Chronic Leukemia Progression After Stem Cell TransplantStephen Cho
One hundred and twenty-nine patients with chronic lymphocytic leukemia (CLL) followed in our outpatient department for periods ranging from 6 months to 13 years were divided into five anatomico-clinical stages: stage O (peripheral and bo... JL Binet,M Lepoprier,G Dighiero,... - 《Cancer》 ...
BCL2B-cell CLL/lymphoma 2××–– BIRC5Baculoviral IAP repeat containing 5××–– C16orf61Chromosome 16 open reading frame 61––×× CCNB1Cyclin B1×××– CENPACentromere protein A––×× DIAPH3Diaphanous homolog 3––×× ERBB2v-erb-b2 erythroblastic leukemia viral oncogene homolog 2×...
Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. The mutational status of tumor immunoglobulin V(H) genes is providing a powerful prognostic marker for chronic lymphocytic leukemia (CLL), with patients ha... Stuart...
There is resurgent interest in glucocorticoids (GCs) in the treatment of poor prognosis chronic lymphocytic leukemia (CLL). Little is known however on how ... J Boelens,S Lust,FV Bockstaele,... - 《Leukemia Research》 被引量: 36发表: 2009年 Protein Tyrosine Phosphatase (PTP or PTPRM), a...
MicroRNA expression profiles can be used to distinguish normal B cells from malignant B cells in patients with chronic lymphocytic leukemia (CLL). We inves... GA Calin,M Ferracin,A Cimmino,... - 新英格兰医药杂志 被引量: 7076发表: 2005年 Intensive integrated therapy of type 2 diabetes: imp...
Controversial data have been reported on the prognostic value of C-X-C motif chemokine receptor 4 (CXCR4) in chronic lymphocytic leukemia (CLL). This prospective, single-center, observational study aimed to evaluate the role of CXCR4 in the pathophysiology of CLL and its prognostic role. A to...
For instance, elevated expression of TRAF1 is linked to the advancement of B lymphocyte malignancies, such as chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and Burkitt’s lymphoma. This progression is primarily due to TRAF1's interaction with TNFRs like CD30 and the Epstein...
ORLANDO, Florida ― The investigational agent venetoclax (under development by AbbVie in partnership with Genentech/Roche) achieved high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), which is associated with a very poor prognosis. ...
Overall survival was accessible for 95% of patients and leukemia-free survival for 88% of patients. The follow-up was 1.7–6.0 years (median, 3.8 years). The incorporation of genomic profiling with cytogenetic and hematologic data improved the risk stratification of patients with MDS. The IPSS-...